机构:[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[2]China National Clinical Research Center for Neurological Diseases, Beijing, China[3]Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China[4]Beijing Translational Engineering Center for 3D printer in Clinical Neuroscience, Beijing, China[5]Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China.
Background: The objective of this study was to elucidate the clinical features, surgical treatment, and long-term outcome in pediatric patients with moyamoya disease (MMD). Methods: We retrospectively reviewed 46 pediatric patients with hemorrhagic MMD at Beijing Tiantan Hospital. Clinical features, radiological findings, and outcomes were analyzed. Results: The mean age at diagnosis was 13.6 +/- 3.6 years. The ratio of girls to boys was 1.0:1.1. Familial occurrence was 4.3%. The primary symptoms at initial presentation were intraventricular hemorrhage (IVH) (47.8%), intracerebral hemorrhage (ICH) (37.0%), ICH with IVH (13.0%), and sub-arachnoid hemorrhage (2.2%). Most patients presented with Suzuki stage 3 or 4 MMD. Posterior cerebral artery involvement was observed in 22 (18.4%) patients. During the average follow-up of 126.1 +/- 96.0 months, 11 of 53 (20.8%) conservatively treated hemispheres and 1 of 36 (2.8%) surgically treated hemispheres experienced a stroke event (P < .05). There was a difference in the Kaplan-Meier curve of stroke between the 2 groups (log rank test, P < .05). What is more, the rate of perfusion improvement in surgically treated patients was higher than in those conservatively treated patients 3 months after discharge (P < .05). Conclusions: Revascularization surgery has a role in the prevention of recurrent strokes and can improve cerebral perfusion in pediatric patients with hemorrhagic MMD. Further study is needed to determine which bypass surgery is more beneficial for pediatric patients with hemorrhagic MMD.
基金:
National Science and Technology Major Project of China [2015BAI12B04]; Program of Beijing Municipal Science and Technology Commission [Z13110200680000]; Program of the National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81371292]; Beijing Municipal Administration of Hospitals' Mission Plan [SML20150501]
第一作者机构:[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[2]China National Clinical Research Center for Neurological Diseases, Beijing, China[3]Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China[4]Beijing Translational Engineering Center for 3D printer in Clinical Neuroscience, Beijing, China[5]Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China.
共同第一作者:
通讯作者:
通讯机构:[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[2]China National Clinical Research Center for Neurological Diseases, Beijing, China[3]Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China[4]Beijing Translational Engineering Center for 3D printer in Clinical Neuroscience, Beijing, China[5]Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China.[*1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
推荐引用方式(GB/T 7714):
Peicong Ge,Qian Zhang,Xun Ye,et al.Clinical Features, Surgical Treatment, and Long-Term Outcome in Children with Hemorrhagic Moyamoya Disease[J].JOURNAL OF STROKE & CEREBROVASCULAR DISEASES.2018,27(6):1517-1523.doi:10.1016/j.jstrokecerebrovasdis.2017.12.047.
APA:
Peicong Ge,Qian Zhang,Xun Ye,Shuo Wang,Dong Zhang&Jizong Zhao.(2018).Clinical Features, Surgical Treatment, and Long-Term Outcome in Children with Hemorrhagic Moyamoya Disease.JOURNAL OF STROKE & CEREBROVASCULAR DISEASES,27,(6)
MLA:
Peicong Ge,et al."Clinical Features, Surgical Treatment, and Long-Term Outcome in Children with Hemorrhagic Moyamoya Disease".JOURNAL OF STROKE & CEREBROVASCULAR DISEASES 27..6(2018):1517-1523